# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Dwight D. Eisenhower (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET015-SYN-TD
- Date: 1956-01-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Russell Okonkwo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week blood pressure and kidney check after increasing lisinopril. **S**

## History of present illness

Mr. Eisenhower returns two weeks after lisinopril was increased to 10 mg and ezetimibe was added. He has had no dizziness, cough, or muscle aches. His home blood pressure has been 124 to 130 over 76 to 80. He is still working half days and walks 40 minutes most days without chest pain or breathlessness. He has not needed nitroglycerin. His echocardiogram and cardiology consultation were done this morning, and he was told he can return to full-time work; he plans to start next week. **S**

| Element | Detail |
|---|---|
| Interval change | No symptoms on the higher lisinopril dose or on ezetimibe |
| Home blood pressure | 124 to 130 over 76 to 80 |
| Exercise | Walking 40 minutes most days without angina |
| Nitroglycerin use | None |
| Adherence | Every dose of aspirin, ticagrelor, atorvastatin, ezetimibe, metoprolol, and lisinopril |
| Work | Half days; full-time return planned next week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; no fever |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea, or ankle swelling |
| Respiratory | Negative | No cough or breathlessness |
| Musculoskeletal | Negative | No muscle aches on statin and ezetimibe |
| Neurological | Negative | No dizziness on standing |
| Hematologic | Positive | Easy bruising on the forearms; no other bleeding |

6 systems reviewed. **S**

## Current medications

- Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Ticagrelor 90 mg oral tablet, one tablet by mouth twice daily **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily **S**
- Lisinopril 10 mg oral tablet, one tablet by mouth daily **S**
- Ezetimibe 10 mg oral tablet, one tablet by mouth daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/78 mmHg; pulse 60 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 78.6 kg; BMI 24.8 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4.6 mmol/L; Creatinine: 1.04 mg/dL; eGFR: 80 mL/min/1.73 m²; Glucose: 94 mg/dL; LVEF by echocardiogram: 52%. All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.6 mmol/L at this visit **S**
- Creatinine: 1 mg/dL at baseline, 1.04 mg/dL at this visit **S**
- eGFR: 84 mL/min/1.73 m² at baseline, 80 mL/min/1.73 m² at this visit **S**
- Glucose: 96 mg/dL at baseline, 94 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well, alert, and eager to get back to work |
| Neck | No jugular venous distension; no carotid bruits |
| Heart | Regular rhythm; no murmur or gallop |
| Lungs | Clear |
| Extremities | No edema; right radial access site healed |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Anterior myocardial infarction about four months ago** (I25.2). Ejection fraction has recovered to 52 percent from 45 percent in the hospital, with only mild apical hypokinesis and no thrombus. No angina. Cardiology agrees he can return to full-time work. **S**
   - Continue aspirin and ticagrelor to complete twelve months after the infarction.
   - Continue metoprolol succinate 25 mg daily; reassess at one year.
   - Full-time work from next week; continue the home walking program.
2. **Essential hypertension** (I10). Blood pressure 128/78 mmHg, below the 130/80 target. Potassium 4.6 and creatinine 1.04 mg/dL (eGFR 80) two weeks after the dose increase, an acceptable change. **S**
   - Continue lisinopril 10 mg daily.
   - Basic metabolic panel every six months.
3. **Hyperlipidemia** (E78.5). Ezetimibe started two weeks ago and tolerated. **S**
   - Lipid panel in about two months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Basic metabolic panel (potassium, creatinine, eGFR) | 1 to 2 weeks after starting or changing an ACE inhibitor, then every 6 months | Completed today | Two weeks after lisinopril was increased to 10 mg. Potassium 4.6, creatinine 1.04 mg/dL, eGFR 80; normal |
| Imaging | Echocardiogram for LVEF reassessment about 40 days after the infarction | Once, about 40 days after the infarction, when the hospital LVEF was reduced | Deferred | The hospital ejection fraction was 45 percent, so a repeat was due about 40 days after the infarction, before he established care here; it was not done. Done today at about four months instead: LVEF 52 percent, so no defibrillator evaluation is needed and no harm resulted. Corrective action: discharge plans from outside hospitals are now reconciled at the intake visit |
| Imaging | Transthoracic echocardiogram | Reassess with clinical change | Completed today | LVEF 52 percent, mild apical hypokinesis, no thrombus or aneurysm, normal valves |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing therapy, then every 3 to 12 months | Due | Ezetimibe added two weeks ago; recheck in about two months |
| Examination | Blood pressure, heart rate, weight and BMI, heart and lungs, edema | Every visit | Completed today | Blood pressure 128/78 mmHg, heart rate 60, weight 78.6 kg |
| Medication safety | Antiplatelet, statin, beta-blocker, and ACE inhibitor adherence and tolerance | Every visit | Completed today | Taking all doses; forearm bruising only; no cough, dizziness, or myalgia |
| Referral | Cardiology evaluation | After the infarction, to establish local cardiology care | Completed today | Seen today; cleared for full-time work and long-distance travel |
| Referral | Cardiac rehabilitation | Within 12 months of the infarction; 36 sessions | Completed today | All 36 phase 2 sessions completed; exit test 9 METs. Continues a home maintenance program |
| Survey | Depression screen (PHQ-2) | Every visit | Up to date | Score 1 at intake two weeks ago; repeat at the lipid review |
| Self-management | Tobacco use | Every visit | Completed today | Abstinent; no exposure at work or home |
| Self-management | Physical activity and Mediterranean-style diet | Every visit | Completed today | Walking 40 minutes most days; diet reviewed |
| Examination | Defibrillator evaluation | At least 40 days after the infarction and 90 days after revascularization if LVEF is 35 percent or less | Not indicated | LVEF 52 percent |

## Goal progress

- Lower LDL cholesterol below 55 mg/dL by the lipid recheck in about two months. In progress; target 1956-03-16. **S**
- Keep blood pressure below 130/80 mmHg. In progress; target 1956-03-16. **S**
- Return to full-time work and travel by the seven-month review. In progress; target 1956-05-11. **S**
- Keep at least 150 minutes a week of moderate exercise after cardiac rehabilitation. In progress; target 1956-05-11. **S**
- Complete twelve months of dual antiplatelet therapy without major bleeding. In progress; target 1956-09-28. **S**

## Guideline basis

- 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025), American College of Cardiology and American Heart Association
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology
- CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026), Aether Forge

## Follow-up

- Lipid panel and review in about two months. Call for chest pain that does not settle with one nitroglycerin tablet in 5 minutes. **S**
- Next scheduled visit 1956-03-16: lipid review nine weeks after adding ezetimibe. **S**
